CIK: 0001687078 · Show all filings
Period: Q2 2022 (← Previous) (Next →)
Filing Date: Aug 11, 2022
Total Value ($000): $359,998 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | 7,648,268 | $98,051 | 27.2% | $40.60 | -72.1% | Common | 230031106 |
| — | iTeos Therapeutics, Inc. | 1,745,943 | $35,966 | 10.0% | $24.67 | — | Common | 46565G104 |
| — | Repare Therapeutics, Inc. | 1,639,849 | $22,941 | 6.4% | $31.02 | — | Common | 760273102 |
| — | Merus N.V. | 919,482 | $20,817 | 5.8% | $17.60 | — | Common | N5749R100 |
| NTLA | Intellia Therapeutics, Inc. | 299,409 | $15,497 | 4.3% | $104.35 | -51.3% | Common | 45826J105 |
| IOVA | Iovance Biotherapeutics Inc Com | 1,200,000 | $13,248 | 3.7% | $13.10 | 0.0% | Common | 462260100 |
| GERN | Geron Corporation | 8,434,991 | $13,074 | 3.6% | $1.34 | +5.3% | Common | 374163103 |
| — | Inhibrx, Inc. | 1,023,325 | $11,615 | 3.2% | $11.35 | — | Common | 45720L107 |
| — | TCR2 Therapeutics, Inc. | 3,370,982 | $9,776 | 2.7% | $14.28 | — | Common | 87808K106 |
| HOWL | Werewolf Therapeutics, Inc. | 2,388,011 | $9,767 | 2.7% | $13.70 | -66.7% | Common | 95075A107 |
| CYTK | Cytokinetics Inc. | 194,246 | $7,632 | 2.1% | $29.44 | +36.7% | Common | 23282W605 |
| CRNX | Crinetics Pharmaceuticals Inc. | 366,676 | $6,839 | 1.9% | $21.72 | -8.1% | Common | 22663K107 |
| BCRX | Biocryst Pharmaceuticals Inc. | 639,089 | $6,762 | 1.9% | $15.77 | -34.6% | Common | 09058V103 |
| TVTX | Travere Therapeutics Inc. | 277,950 | $6,735 | 1.9% | $18.37 | +36.9% | Common | 89422G107 |
| — | YmAbs Therapeutics, Inc. | 443,702 | $6,713 | 1.9% | $30.56 | — | Common | 984241109 |
| HRMY | Harmony Biosciences Hldgs Inc. | 137,517 | $6,707 | 1.9% | $32.20 | +39.8% | Common | 413197104 |
| — | Harpoon Therapeutics, Inc. | 3,196,707 | $6,106 | 1.7% | $14.79 | — | Common | 41358P106 |
| MIRM | Mirum Pharmaceuticals Inc. | 288,531 | $5,615 | 1.6% | $16.26 | +45.0% | Common | 604749101 |
| ARQT | Arcutis Biotherapeutics inc | 258,500 | $5,509 | 1.5% | $16.92 | +21.3% | Common | 03969K108 |
| — | Reata Pharmaceuticals inc-a | 180,000 | $5,470 | 1.5% | $32.76 | — | Common | 75615P103 |
| FOLD | Amicus Therapeutics Inc. | 495,603 | $5,323 | 1.5% | $10.23 | -19.5% | Common | 03152W109 |
| — | Epizyme, Inc. | 3,425,202 | $5,035 | 1.4% | $15.19 | — | Common | 29428V104 |
| — | G1 Therapeutics, Inc. | 856,798 | $4,233 | 1.2% | $25.71 | — | Common | 3621LQ109 |
| — | Verastem, Inc. | 3,244,650 | $3,764 | 1.0% | $2.94 | — | Common | 92337C104 |
| MDGL | Madrigal Pharmaceuticals inc | 45,000 | $3,221 | 0.9% | $73.50 | 0.0% | Common | 558868105 |
| — | Inozyme Pharma Inc. | 664,980 | $3,172 | 0.9% | $7.80 | — | Common | 45790W108 |
| — | Oncorus, Inc. | 2,377,031 | $2,995 | 0.8% | $32.33 | — | Common | 68236R103 |
| RVMD | Revolution Medicines, Inc. | 146,041 | $2,846 | 0.8% | $29.11 | -33.1% | Common | 76155X100 |
| ADCT | ADC Therapeutics, Inc. | 334,384 | $2,658 | 0.7% | $33.59 | -71.8% | Common | H0036K147 |
| — | Karuna Therapeutics inc | 20,000 | $2,530 | 0.7% | $126.80 | — | Common | 48576A100 |
| — | Provention Bio Inc | 592,435 | $2,370 | 0.7% | $4.00 | — | Common | 74374N102 |
| — | ESSA Pharma, Inc. | 660,892 | $2,082 | 0.6% | $8.00 | — | Common | 29668H708 |
| PHAT | Phathom Pharmaceuticals inc | 193,326 | $1,632 | 0.5% | $16.15 | -36.4% | Common | 71722W107 |
| NEO | Neogenomics Inc. | 135,573 | $1,105 | 0.3% | $46.29 | -79.4% | Common | 64049M209 |
| — | Avadel Pharmaceuticals Plc | 412,363 | $1,006 | 0.3% | $9.53 | — | ADR | 05337M104 |
| — | AVROBIO, Inc. | 647,918 | $596 | 0.2% | $5.58 | — | Common | 05455M100 |
| BDTX | Black Diamond Therapeutics, Inc. | 239,888 | $590 | 0.2% | $9.87 | -76.5% | Common | 09203E105 |